EmailHospital Circular 20/2007
Date issued: 26 September 2007
Distribution: Public hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 October 2007
We have had recent advice from the Commonwealth Government of changes to the Highly Specialised Drugs Program, effective 1 October 2007.
ADDED ITEMS:
Infliximab (Crohn’s disease in paediatric patients) |
|||||
| 9612X | Powder for IV infusion 100mg | 1 | Remicade | $751.70 | SH |
Infliximab (Crohn’s disease in adult patients) |
|||||
| 9613Y | Powder for IV infusion 100mg | 1 | Remicade | $751.70 | SH |
| Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | |||||
PRICE DECREASE:
Infliximab (Active ankylosing spondylitis, severe active psoriatic arthritis and severe active rheumatoid arthritis) |
|||||
| 6448J | Powder for | 1 | Remicade | $751.70 | SH |
| 6496X | IV infusion 100mg | ||||
| 6397Q | |||||
Tenofovir disoproxil fumarate (from 1 August 2007) |
|||||
| 6358P | Tablet 300mg | 30 | Viread | $483.10 | GI |
Tenofovir disoproxil fumarate with Emtricitabine (from 1 August 2007) |
|||||
| 6468K | Tablet 300mg - 200mg | 30 | Truvada | $765.10 | GI |
| Agreed prices available on the Commonwealth/State Highly Specialised Drugs Program Guidelines website. | |||||
DELETED BRAND:
| Clozapine | ||||
| 6101D | Tablet 25mg | 100 | CloSyn | ZT |
| 6102E | Tablet 100mg | 100 | CloSyn | ZT |
| Brand discontinued by manufacturer and not subsidised from 1 October 2007 | ||||
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Approved by
Dr Jennifer King
Director, Programs
Metropolitan Health & Aged Care Services
